The stock of Antares Pharma Inc (NASDAQ:ATRS) hit a new 52-week high and has $2.13 target or 5.00% above today’s $2.03 share price. The 6 months bullish chart indicates low risk for the $328.22 million company. The 1-year high was reported on Nov, 25 by Barchart.com. If the $2.13 price target is reached, the company will be worth $16.41M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 3.57% or $0.07 during the last trading session, hitting $2.03. About 669,490 shares traded hands or 33.43% up from the average. Antares Pharma Inc (NASDAQ:ATRS) has risen 92.16% since April 22, 2016 and is uptrending. It has outperformed by 86.75% the S&P500.
Analysts await Antares Pharma Inc (NASDAQ:ATRS) to report earnings on March, 14. They expect $-0.04 EPS, 0.00% or $0.00 from last year’s $-0.04 per share. After $-0.04 actual EPS reported by Antares Pharma Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy.”
Insitutional Activity: The institutional sentiment increased to 0.82 in Q2 2016. Its up 0.19, from 0.63 in 2016Q1. The ratio improved, as 28 funds sold all Antares Pharma Inc shares owned while 21 reduced positions. 16 funds bought stakes while 15 increased positions. They now own 55.56 million shares or 16.31% less from 66.39 million shares in 2016Q1.
Moreover, Blackrock Advsrs Ltd has 0% invested in Antares Pharma Inc (NASDAQ:ATRS) for 26,095 shares. Broadfin Ltd Co last reported 14.89M shares in the company. Kingdon Cap Ltd Liability holds 0.07% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS) for 1.28M shares. Schwab Charles Mgmt Inc accumulated 0% or 217,598 shares. Citigroup owns 8,362 shares or 0% of their US portfolio. Lmr Prtn Limited Liability Partnership holds 0.05% or 282,738 shares in its portfolio. Sii Invests Wi accumulated 10,100 shares or 0% of the stock. Renaissance Technology Ltd Liability Com has 2.72 million shares for 0.01% of their US portfolio. William Harris Investors Inc has 0.46% invested in the company for 1.74M shares. Credit Suisse Ag holds 0% or 537,318 shares in its portfolio. Moreover, Oppenheimer & Com has 0% invested in Antares Pharma Inc (NASDAQ:ATRS) for 112,300 shares. Courage Cap Management Limited Company reported 450,000 shares or 0.26% of all its holdings. Blackrock Fund Advisors reported 26,842 shares or 0% of all its holdings. California Employees Retirement Sys last reported 0% of its portfolio in the stock. Millennium Mgmt Limited Liability Corp holds 1.28 million shares or 0% of its portfolio.
More recent Antares Pharma Inc (NASDAQ:ATRS) news were published by: Globenewswire.com which released: “Antares Pharma to Present at the 28th Annual Piper Jaffray Healthcare Conference” on November 23, 2016. Also Seekingalpha.com published the news titled: “Antares Pharmaceuticals: The Stock To Buy On EpiPen Issues” on August 28, 2016. Globenewswire.com‘s news article titled: “Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief …” with publication date: October 31, 2016 was also an interesting one.
ATRS Company Profile
Antares Pharma, Inc. (Antares), incorporated on April 29, 2005, is a specialty pharmaceutical firm that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Firm develops and makes pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Firm makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Firm operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.